ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Fundamental Analysis
USA - NASDAQ:ALNY - US02043Q1076 - Common Stock
449.16 USD
-4.81 (-1.06%)
449.16 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to ALNY. ALNY was compared to 531 industry peers in the Biotechnology industry. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNY shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ALNY was profitable.
In the past year ALNY has reported a negative cash flow from operations.
ALNY had negative earnings in each of the past 5 years.
In the past 5 years ALNY reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.99%, ALNY belongs to the top of the industry, outperforming 86.63% of the companies in the same industry.
The Return On Equity of ALNY (-127.33%) is worse than 60.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.99% | ||
| ROE | -127.33% | ||
| ROIC | N/A |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALNY's Gross Margin of 83.64% is amongst the best of the industry. ALNY outperforms 86.44% of its industry peers.
ALNY's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALNY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNY has been increased compared to 1 year ago.
ALNY has more shares outstanding than it did 5 years ago.
ALNY has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.03 indicates that ALNY is not in any danger for bankruptcy at the moment.
ALNY has a Altman-Z score of 7.03. This is in the better half of the industry: ALNY outperforms 78.91% of its industry peers.
A Debt/Equity ratio of 4.10 is on the high side and indicates that ALNY has dependencies on debt financing.
ALNY's Debt to Equity ratio of 4.10 is on the low side compared to the rest of the industry. ALNY is outperformed by 82.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.03 |
ROIC/WACCN/A
WACC8.69%
2.3 Liquidity
ALNY has a Current Ratio of 2.80. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.80, ALNY is doing worse than 65.16% of the companies in the same industry.
ALNY has a Quick Ratio of 2.75. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY's Quick ratio of 2.75 is on the low side compared to the rest of the industry. ALNY is outperformed by 64.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
ALNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 119.47%, which is quite impressive.
The Revenue has grown by 22.97% in the past year. This is a very strong growth!
The Revenue has been growing by 59.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
3.2 Future
The Earnings Per Share is expected to grow by 74.37% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 34.80% on average per year.
EPS Next Y167.09%
EPS Next 2Y119.91%
EPS Next 3Y95.36%
EPS Next 5Y74.37%
Revenue Next Year63.17%
Revenue Next 2Y51.94%
Revenue Next 3Y43.23%
Revenue Next 5Y34.8%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 880.71, which means the current valuation is very expensive for ALNY.
88.51% of the companies in the same industry are more expensive than ALNY, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.89, ALNY is valued quite expensively.
A Price/Forward Earnings ratio of 72.99 indicates a quite expensive valuation of ALNY.
ALNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALNY is cheaper than 87.95% of the companies in the same industry.
ALNY is valuated expensively when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 880.71 | ||
| Fwd PE | 72.99 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALNY does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ALNY's earnings are expected to grow with 95.36% in the coming years.
PEG (NY)5.27
PEG (5Y)N/A
EPS Next 2Y119.91%
EPS Next 3Y95.36%
5. Dividend
5.1 Amount
ALNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
449.16
-4.81 (-1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.86%
Inst Owner Change-0.08%
Ins Owners0.2%
Ins Owner Change6.34%
Market Cap58.88B
Revenue(TTM)2.25B
Net Income(TTM)-319.09M
Analysts79.44
Price Target466.31 (3.82%)
Short Float %3.18%
Short Ratio3.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.91%
Min EPS beat(2)30.6%
Max EPS beat(2)57.21%
EPS beat(4)3
Avg EPS beat(4)22.4%
Min EPS beat(4)-2.21%
Max EPS beat(4)57.21%
EPS beat(8)7
Avg EPS beat(8)54.7%
EPS beat(12)9
Avg EPS beat(12)30.18%
EPS beat(16)9
Avg EPS beat(16)17.36%
Revenue beat(2)1
Avg Revenue beat(2)7.46%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)15.49%
Revenue beat(4)1
Avg Revenue beat(4)1.67%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)15.49%
Revenue beat(8)4
Avg Revenue beat(8)19.36%
Revenue beat(12)6
Avg Revenue beat(12)11.5%
Revenue beat(16)7
Avg Revenue beat(16)6.42%
PT rev (1m)1.66%
PT rev (3m)9.92%
EPS NQ rev (1m)36.91%
EPS NQ rev (3m)309.27%
EPS NY rev (1m)25.14%
EPS NY rev (3m)204.95%
Revenue NQ rev (1m)2.88%
Revenue NQ rev (3m)10.97%
Revenue NY rev (1m)3.76%
Revenue NY rev (3m)23.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 880.71 | ||
| Fwd PE | 72.99 | ||
| P/S | 23.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 234.95 | ||
| P/tB | 234.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.51
EY0.11%
EPS(NY)6.15
Fwd EY1.37%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS18.78
BVpS1.91
TBVpS1.91
PEG (NY)5.27
PEG (5Y)N/A
Graham Number4.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.99% | ||
| ROE | -127.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.64% | ||
| FCFM | N/A |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score2
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.69% | ||
| Cap/Sales | 1.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 7.03 |
F-Score2
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
EPS Next Y167.09%
EPS Next 2Y119.91%
EPS Next 3Y95.36%
EPS Next 5Y74.37%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
Revenue Next Year63.17%
Revenue Next 2Y51.94%
Revenue Next 3Y43.23%
Revenue Next 5Y34.8%
EBIT growth 1Y-275.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year485.62%
EBIT Next 3Y150.05%
EBIT Next 5Y137.57%
FCF growth 1Y90.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.71%
OCF growth 3YN/A
OCF growth 5YN/A
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ALNY.
What is the valuation status of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ChartMill assigns a valuation rating of 2 / 10 to ALNYLAM PHARMACEUTICALS INC (ALNY). This can be considered as Overvalued.
How profitable is ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a profitability rating of 2 / 10.
What is the financial health of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The financial health rating of ALNYLAM PHARMACEUTICALS INC (ALNY) is 4 / 10.
What is the expected EPS growth for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The Earnings per Share (EPS) of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 167.09% in the next year.